Dose-dependent effects of haloperidol (2.66 nmollkg to 79.8 mmollkg, IP) on levels of dopamine, homovanillic acid (HVA) and dihydroxyphenylacetic acid (DOPAC) were assessed in the corpus striatum, nucleus accumbens, and medial prefrontal cortex (PFCTX) of 18-, 30-, and 110-day-old rats. Eighteen-day-old rats were 35% and 63% more sensitive than adults to the effects of haloperidol on striatal and accumbens turnover and had steeper dose-response curves. The dose-response function in the PFCTX was similar to striatum at 18 days, but KEY WORDS: Haloperidol; Dopamine; Corpus striatum; Nucleus accumbens; Prefrontal cortex; Development
Haloperidol is a prototypical neuroleptic agent that has value throughout the lifespan in the treatment of psy chotic disorders and behavioral agitation (e.g., Baldes sarini, 1985) . Some clinical data are available to guide dosing with this or other antipsychotic agents in adults (Baldessarini et al. 1989 ), but much less is known about optimal dosing in childhood or adolescence (Teicher and Glod 1989) . A rational initial approach is to ascer tain whether there are important developmental differ ences in the behavior and neuropharmacologic effects became shallower and nonsigmoidal with age. Maximally effective doses of haloperidol produced, at all ages, a comparable percent rise in DOPAC levels in all regions. With maturation, the percent rise in HV A progressively outstripped DOPAC response in nucleus accumbens and striatum. Overall, prominent developmental differences emerged in these regions in their sensitivity and response to haloperidol, which are consistent with previously reported differences in behavioral sensitivity.
INeuropsychopharmacology 9: 147-156, 1993J of this representative agent on laboratory animals. Studies by Campbell and Baldessarini and colleagues (Campbell and Baldessarini 1981; Campbell et al. 1988) found that developing rats are much more sensitive to the acute behavioral effects of neuroleptics than adults. The EDso for haloperidol-induced catalepsy, sedation (ptosis), and bradykinesia, respectively, was 16-, 60-, and 75-fold lower in 1-month-old rats than in 18-month old rats (Campbell and Baldessarini 1981) . These differ ences were not accounted for by drug disposition fac tors. First, similar age differences occurred in response to a chemically dissimilar neuroleptic, perphenazine (Campbell et al. 1988) . Even more signifIcantly, paral lel age differences in dose response to haloperidol and perphenazine were obtained following direct intracere broventricular administration, which bypassed the effects of peripheral metabolism, distribution, and blood-brain barrier penetration (Campbell et al. 1988 ). These observations strongly suggest that there are im portant pharmacodynamic differences across age in sen sitivity to neuroleptic agents. Supporting these fIndings are receptor-binding studies that reveal prominent changes in the density of 01 and D2 dopamine (DA) receptors in the striatum of developing rats (Gelbard et al. 1989) . 01 and D2 receptor density at puberty (40 days) was, respectively, 2.3-and 4. 0-fold greater than in early adulthood (120 days). A simllar ontogenetic pat tern has also been observed in man (Seeman et al. 1987 ). With such marked developmental changes in DA recep tor density, it would be surprising if there were no differences in pharmacodynamic response.
In the present study we sought to ascertain whether there are major developmental differences in acute re gional response of ascending forebrain DA systems to systemically administered haloperidol. Tissue concen trations of DA, homovanillic acid (HV A), and dihy droxyphenylacetic acid (DOP AC) were quantifIed in the corpus striatum, nucleus accumbens, and medial prefrontal cortex (PFCTX) following acute challenge with a range of doses of haloperidol, to provide data on age-related changes in nigrostriatal and mesocor ticolimbic DA system sensitivity and responsiveness to this drug.
MATERIALS AND METHOD

Animals
Sprague-Dawley rats were obtained from Charles River Laboratories. Eighteen-day-old preweaning rats and 30-day-old peripubertal rats of both sexes were raised in our colony from litters born to mUltiparous mothers shipped on the day following delivery. Young adult male rats (110 days old) were purchased from the same source and adapted to the colony for at least 1 week prior to study. Animals were maintained on a conven tional 0700 to 1900 hour light-dark cycle. Food and wa ter were available ad libitum. Eighteen day olds resided with their natural litters (10 to 12 pups). Thirty-day-old NEUROPSYCHOPHARMACOLOGY 1993-VOL. 9, NO.2 animals were weaned on day 22 and were housed in hanging wire group cages with same-sex littermat es. Adult rats also were group housed (4 per cage) in simi· lar cages. Altogether, 215 animals were used as sub· jects in this study.
Drug Administration and Dosing
Haloperidol (donated by McNeil Laboratories) was di s· solved in one or two drops of 1 mol lactic acid, diluted in distilled water, and adjusted to a pH of between 5.0 and 5.5, for administration by intra-peritoneal (IP) in· jection in volumes of 0.5 mI/kg, at doses ranging from ll1g to 30 mg per kilogram of body weight (2.66 nmoll kg to 79.8 mmollkg). The maximum dose of haloperidol studied at each age was selected to be sublethal, but to produce maximal or declining levels of metabolites in striatal tissue and to mimic or exceed the full range of dosages used in clinical practice. For 18-day-old animals, the maximum dose of haloperidol was limited to 3 mg/kg (7.98 mmollkg), for 30-day-olds it was 10 mg/kg (2.66 mmollkg) and for 100-day-olds it was 30 mg/kg (79.8 mmol/kg). Vehicle controls received injec· tions of 0.01 mmol lactic acid adjusted to a pH of be· tween 5.0 and 5.5. Injections occurred between 1000 and 1400 hours to minimize circadian variation in reo sponse noted previously (Campbell and Baldessarini 1982) . Following drug administration, 18-day-old rats were returned to their home cage, whereas 30-day and 110-day-old subjects were placed with their usual cag e· mates in plastic group cages. The doses and number of subjects per cell are summarized in Table 1 .
Regional Brain Dissection
Animals were sacrihced by decapitation 2 hours after drug administration. The brain was removed, sprayed with ice-cold isotonic saline, and cut into 1.5-to 2.0-mm Striatum  16  6  10  12  6  12  6  6  Accumbens  16  6  10  8  6  10  6  6  PFCTX  8  2  4  5  4  5  30-day-alds  Striatum  19  11  12  6  8  6  5  4  Accumbens  19  5  12  6  10  6  6  4  PFCTX  8  2  2  6  5  6  4  110-day·alds  Striatum  17  2  2  6  12  5  6  4  10  Accumbens  18  2  2  6  10  6  7  4  7  PFCTX  8  2  2  6  6  5  4 coronal sections on a micrometer-mounted cutting ped estal (Stoelting tissue chopper). Sequential forebrain slabs were placed on an iced Petri dish, striatum and nucleus accumbens were removed by freehand dissec tion, and PFCTX was removed for a selected subset of brains (Teicher et al. 1986 (Teicher et al. , 1991 . Specimens were weighed and stored at -70DC until analysis. The num ber of individual sections assayed from each region is indicated in Table 1 .
18-day·alds
Regional Brain Analysis
Tissue concentrations of DA, HV A, and DOPAC were determined by high-pressure liquid chromatography w i th EC) as described in detail elsewhere (Baldessarini et al. 1990 ). Individual samples were homogenized in 0.1 N perchloric acid solution (PCA) containing 0.1 mmol Na2 ethylenediaminetetraacetic acid (EDTA), 0.4 mmol sodium metabisulbte and 3, 4-dihydroxybenzylamine (DHBA) as internal standard. After a 5-minute centrifu gation (9,000 x g), the supernatant, in 100 /ll samples, was injected into a Rainin Rabbit HP Solvent Delivery System (1.0 ml/min), separated on a Rainin C18 reverse phase 5-/lm column (4.6 mm x 25 cm), and detected am perometrically using a Bioanalytical Systems (Model
LC-4B).
:For striatum and accumbens, DOPAC and HV A were analyzed by direct injection of the supernatant, and DA was analyzed after alumina extraction (Bal dessarini et al. 1990 ). In PFCTX, DOPAC, HVA, and DA were analyzed in a single run by direct injection of the sample supernatant. The mobile phase for this assay consisted of 0.1 mol sodium acetate, 0.2 mmol Na2EDTA, 0.5 mmol 1-heptane sulfonic acid, 12% (vols) methanol, adjusted to pH 5.0 with glacial acetic acid (HPLC grade, Fisher Scientibc) , and detected at +0.75V using a glassy carbon analytical electrode and an Ag/AgCl reference electrode. Aberrant HPLC results (more than 3 standard deviations from the mean) were eliminated prior to data analysis, as they most likely reflected errors in dissection, storage, or analysis.
Statistical Analysis
Dose-response data were quantibed using a Macintosh version of ALLFIT (DeLean et al. 1978) written by M. Teicher. Neurochemical data were bt to a four-parameter logistic model with minimum and maximum response levels set equal to effects obtained at zero dose and at maximally effective dose. Computerized curve btting yielded values (± SEM) for slope and ED50. Age differ ences were ascertained by simultaneous constrained curve btting, which determines an F-ratio for the SignifIcance in degradation in goodness-of-bt, when the pr ogram was required to calculate a parameter forced Developmental Diff erences in Response to Haloperidol 149 to be equal between age groups (DeLean et al. 1978) . For biphasic dose-response functions, ALLFIT was used to model response to the ascending aspect of the curve, which included the peak and subsequent pla teau phase (within 15% of peak).
Several comparisons are expressed as percent change from the baseline (vehicle control) condition. Whenever this conversion was made, the SEM was cal culated using a statistical procedure that takes into ac count both the variability in the treatment group and the variability in the vehicle-treated control condition (McLean and Welch 1971) .
Differences between groups in basal and maximal stimulated levels of DA metabolites were determined using analysis of variance procedures for unequal sam ple sizes (Keppel 1973) . Planned comparisons between specibc ages and conditions were evaluated using Stu dent's t-tests. Data are reported as means ± SEM un less stated otherwise. Nonsignibcant diff erences are in dicated as "NS."
RESULTS
Striatum
Developmental Differences in Basal Metabolite Concen trations and Metabolite-to-Transmitter Ratios. Dopa mine levels in striatum were only 48% ± 5% of adult levels at 18 days (p < .0001), and 75% ± 7% at 30 days (p < .0001). There were also signibcant developmental diff erences in basal levels of HVA and DOPAC (Table  2) . Levels of HV A were slightly greater at 18 and 30 days than in adults (p < .02), whereas DOPAC levels were substantially lower at 18 days than at 30 days (p < .0001) or adulthood (p < .0001). Thus, the basal ratio of HVA to DOPAC changed markedly with age (F = 51.5, P < .0001). At 18 days, HVA levels were 87% ± 4% as high as DOPAC levels. At 30 days, basal HV A levels had fallen to 57% ± 2% of DOPAC levels, and at 110 days they were only 46% ± 2%. These alterations in levels of HV A and DOPAC suggest major developmental differences in the way DA is metabolized. Metabolite to-transmitter ratios ([HVA+ DOPAq/DA) were cal culated as an estimate of overall DA turnover. This ra tio changed substantially during development (F = 23.6, P < .0001). Dopamine turnover was 58% ± 9% greater at 18 days and 25% ± 6% greater at 30 days than in early adulthood (p < .0002).
Age Differences in Sensitivity to the Effects of Haloperi dol on Striatal DA Metabolism. There were strong de velopmental differences in sensitivity to haloperidol based on the combined metabolite response (F = 11.8, P < .001) or metabolite/transmitter ratios (F = 23.8, P < .0001; Fig. 1 ). As seen in Table 2 , the dose of halo peridol necessary to produce a half-maximal DA me tabolite response in striatal tissue was much lower dur- 
•.
•. y..... 18 and 30 days were approximately 71 % ± 11% of adult levels. Overall, in this subcortical limbic region, the pri mary effect of age was a shift in the production of HV A and DOPAC, with 18-day-old rats producing relatively more HV A and less OOPAC. Metabolite-to-transmitter ratios increased slightly after 30 days of age.
Age Differences in Sensitivity to the Effects of Halo peridol on Mesolimbic DA System Response. There were prominent age diff erences in the E050 of the metabolite-to-transmitter ratio (F = 15.1, p< .001). The
EDso was lowest at 18 days, nonsignibcantly greater at 30 days, but substantially greater at 110 days (171 % ± 26%; p< .0001; Table 3 ). The slope of the dose-response function also changed markedly with age. It was not possible to accurately determine the slope at 30 days, as HV A and OOPAC responses increased from basal levels at 0.06 mg/kg (160 nmol/kg), to maximum levels atO.l0 mg/kg (266 nmol/kg) of haloperidol. The dose-re sponse function was less steep at 18 days and even less steep at 110 days (Fig. 2) . Overall, in the nucleus accumbens, 30-day-old rats were more sensitive (lower E050 and EDmax) to the effects of haloperidol, as indicted by accumulation of HV A or OOPAC, and also displayed a very steep, vir tually quantal, dose-response function, suggesting less efficient modulation and regulation at that age. Sensi tivity of the metabolite responses was similar at 18 and 110 days of age, although the youngest rats were more sensitive to the effects of haloperidol on metabolite-to transmitter ratios and had steeper dose-response func tions than the adults.
Frontal Cortex
Developmental Differences in Basal Metabolite Concen trations and Metabolite-to-Transmitter Ratios. There were no signifIcant differences between ages in basal cortical levels of OA. Levels of HVA were 64% ± 24% greater at 18 days (p < .01), and 52% ± 19% greater at 30 days (p < .01) than in adults (Table 4) . Levels of OOPAC also varied across age, but in the opposite direction. Levels at 18 days were only 45% ± 24% of adult levels (p < .05). Turnover rates, based on com bined metabolite-to-transmitter ratios, were marginally 1.0-3.0 across age. Both 18-and 30-day-old animals were many fold more sensitive to the effects of haloperidol than were 110-day-olds. Curiously, there was no signifIcant age difference in sensitivity to the effects of haloperidol on combined metabolite-to-transmitter ratios (Fig. 3) .
Regional Differences Within Each Age
Basal Levels. Levels of DA, HV A, and DOPAC were very much lower in the PFCTX than in striatum or accumbens at each age. At 18 days, there were no significant differences between striatum and accumbens in levels of DA or DOP AC, but HV A levels were slightly greater in the striatum (p < .02). At 30 days, striatal lev els of DA and HV A exceeded accumbens levels by 33% and 50% respectively (p < .03). At 110 days, DA levels in striatum were 77. 5% ± 26.6% greater than in accum bens (p < .00001) although there were no differences in metabolite levels between these regions. Thus, with maturation, there was a progressive increase in DA lev els in striatum relative to accumbens. As shown in Fig ure 4, combined metabolite-to-transmitter ratios in stri atum and accumbens were equivalent at 18 days, but 32.1 % ± 9.7% greater in accumbens at 30 days (p < .002), and 131. 7% ± 30.9% greater at 110 days (p < .0001).
Hence, with maturation, there was a progressive in crease in turnover rates in the accumbens relative to the striatum. At each age, estimated turnover rates in the PFCTX markedly exceeded those in the striatum by 1.9-to 3.0-fold (p < .00001). At 18 and 30 days, PFCTX turnover rates also greatly exceeded those in the accum bens (1.8-to 2-fold; p < .00001); however, at 110 days, metabolite-to-transmitter ratios in the PFCTX were not significantly greater than in the accumbens (1.3-± 0.3-fold, P > .13). This lack of difference was due, in part, to a continued increase in accumbens turnover and a decrease in PFCTX turnover ratios (Fig. 4 ). There were also relatively consistent differences be tween regions in the ratio of HV A to DOP AC. These ratios in PFCTX were 1.6-to 2.4-fold greater than those in the striatum at each age (p < .00001). Striatal HVA to DO PAC ratios, in turn, exceeded those in the accum bens by 30% to 51% (p < .007) across age.
Sensitivity. There were dramatic differences between regions in sensitivity to haloperidol at each age. Of greatest importance may be the combined metabolite- to-transmitter ratios ([HV A + OOPAqIDA; Fig. 5 ). In 18-day-old animals, E050 for this function was lowest in PFCTX, 218% ± 40% greater in striatum (p < .004), and 378% ± 48% greater in accumbens (p < .0001). At 30 days, the E050 value for PFCTX was 15 times lower than in the accumbens (p < .00001), and 36-fold lower than in striatum (p < .01). At 110 days, the E050 was also far lower in PFCTX than in the other regions and signifIcantly greater in accumbens than striatum. In short, metabolite-to-transmitter ratios in the PFCTX were far more sensitive to haloperidol than in accum bens and striatum at each age tested. At 18 and 110 days, the striatum was 50% to 160% more sensitive than the accumbens, whereas at 30 days, the accumbens was 138% more sensitive than the striatum.
DISCUSSION
Prominent developmental differences were observed in the neurochemical response of forebrain OA systems to systemic haloperidol. The primary question we sought to answer was whether the immature OA sys tem was more sensitive to the acute effects of halo peridol (lower E050). In comparison to young adult rats, pre weaning rats (18 days old) were 35% more sen sitive to the effects of haloperidol on striatal turnover ([HV A + OOPAq/OA) and 63% more sensitive to the effects of haloperidol on accumbens turnover. Thirty day-old peri pubertal rats were approximately 67% more sensitive to the effects of haloperidol on this estimate of OA turnover in the nucleus accumbens, but 106% less sensitive to the effects of haloperidol on turnover in the striatum. We compared these neuropharmaco-
logic results to differences in behavioral sensitivity reported by Campbell and Baldessarini (1981) in rats of comparable age. A strong correlation emerged be tween sensitivity (E05O) to the effects of haloperidol on striatal turnover and sensitivity to the effects of this agent on catalepsy (r = 0.969). There was no relation ship between turnover sensitivity in the accumbens and sensitivity to catalepsy (r = -0.082). Sensitivity to the sedative effects of haloperidol correlated more strongly with turnover sensitivity in the accumbens (r = 0.694) than in striatum (r = 0.456) but correlated even more strongly with sensitivity in the PFCTX (r = -0.934).
Note however that this was a negative correlation, in dicating that high sensitivity to haloperidol effects on turnover in the PFCTX was associated with low sensiti vity to the sedative effects of haloperidol. Sensitivity to the locomotor activity-inhibiting effects of haloperidol was more strongly associated with turnover in the stri atum (r = 0.887) than accumbens (r = 0.150), but was highly negatively associated with turnover in the PFO'X (r = -0.968). Nevertheless, with assessment in only three ages, it is difti.cult to make much of these correla tions other than to generate hypotheses. Our observa tions suggest that sensitivity to the cataleptic effects of haloperidol may be most directly related to turnov er sensitivity in the striatum. Sensitivity to sedation may be directly related to sensitivity to haloperidol in the accumbens and inversely related to sensitivity in the PFCTX. Similarly, sensitivity to locomotor inhibition may be directly related to striatal sensitivity and in· versely related to PFCTX sensitivity. Additional ages will need to be studied to evaluate these associations more adequately. These observations are consistent with studies that show that selectively depleting DA in PFCTX increases activity and arousal (Carter and Py cock 1980; Bubser and Schmidt 1990) , presumably through inhibitory pathways to striatum and accurn bens. It is thus likely that the extremely high sensitiv ity of 18-day-old rats to the behavioral effects of halo peridol was a consequence of relatively high sensitivity in striatum and accumbens and possibly lower sensi tivity in the PFCTX. There were very prominent developmental diff er ences in OA turnover response to haloperidol in the PFCTX. At 18 days, OA turnover in the PFCTX followed a typical sigmoidal dose-response function, similar to such curves in the accumbens and striatum. While 3(). day-old and adult rats had prominent sigmoidal re sponse curves in striatum and accumbens (Figs. 1 and 2), they had a nearly flat response in PFCTX (Fig. 3) . The slope of the dose-response curve in PFCTX was 10-fold greater at 18 days than at 30 or 110 days. Ban non et al. (1982, 1983) previously reported that the adult PFCTX displays relatively little compensatory change in activity following acute neuroleptic challenge and fails to develop tolerance to repeated neuroleptic treat-ment. They postulated that this was a consequence of the lack of presynaptic synthesis-modulating DA au toreceptor function. The more prominent sigmoidal re sponse of the PFCTX in 18-day-old rats may be related to the recent observation of Teicher et al. (1991) that there appears to be a transient population of synthesis modulating D1-like autoreceptor in the PFCTX of the developing rat. Dopamine 01 receptor-mediated mod ulation of DA synthesis in the PFCTX was present from 15 to 22 days of age but faded thereafter. The present fmdings suggest that the PFCTX is not very different from striatum and accumbens in its response to halo peridol at 18 days, but develops a more unique response pattern with maturation.
Our fmdings also indicate that there were signifi cant developmental differences in production of HV A and DOP AC. In all three major forebrain target regions, there was a progressive developmental decline in HV A levels and a progressive increase in DOPAC levels. Keller et al. (1973) have proposed that a large fraction ofDOPAC results from leakage of DA from storage sites into cytosol and is thus strongly influenced by endoge nous DA levels. Coyle and Molliver (1977) have also shown that the immature brain has a remarkable, al beit unused, capacity to store catecholamines. Thus, cytosolic leakage may also be affected by developmen t a l diff erences in DA storage capacity and levels. It is interesting that haloperidol produced a comparable per cent rise in DOPAC levels at each age in all regions. In contrast, the percent rise in HV A levels in striatum and accumbens following maximally effective doses of haloperidol was progressively greater at 30 and 110 days. Released DA transported back into DA neurons ismetabolized, largely, into DOPAC. Homovanillic acid predominantly derives from DA that is initially metabo lized extraneuronally (Keller et al. 1973) . Thus, our ob servations suggest that, in adult accumbens and stria tum, maximally stimulated DA release can significantly outstrip reuptake capacity. In future studies it will be useful to measure 3-methoxytyramine, as a more di rect indicator of DA release (Kehr 1976; Nissbrandt and Carlsson 1987) and to provide more comprehensive pharmacologic estimates of turnover and tyrosine hy droxylase activity (Nissbrandt and Carlsson 1987) .
Although one must be very cautious in extrapolat ing fmdings from rats to man, it is reasonable to pon der whether the present findings have any clinical im plications or correlates. First, it is apparent that there were significant changes is the neuropharmacologic properties of the PFCTX between the ages studied. Turnover response in the PFCTX was very different in preweaning prepubertal rats and peripubertal rats at 30 days. There were also marked differences between 3O-day-old and adult rats in the degree of basal turnover of DA and the level of accumulation its metabolites. These age-dependent differences in pharmacologic Developmental Differences in Response to Haloperidol 155 properties of the PFCTX may have some relationship to the age of onset of schizophrenia. Childhood cases fulfIlling adult criteria for schizophrenia are rare (Kydd and Werry 1982) . The majority of cases emerge between 15 and 35 years of age (Babigian 1980) . Weinberger (1987) has formulated an important neurodevelopmen tal theory, which proposes that a fixed lesion present in early life is ultimately responsible for schizophrenia. However, this lesion may be relatively silent during childhood until normal maturational events unfold, possibly in the PFCTX, which then enable the effect of the lesion to become more fully manifest. The present findings clearly show prominent diff erences between the ages studied in the pharmacologic response prop erties of the PFCTX. This may be due to the transient expression of PFCTX DA autoreceptor-like function (Teicher et al. 1991) . By suppressing DA synthesis dur ing periods of high neuronal activity, such a mecha nism may normally help to protect against the expres sion of psychotic illness during the prepubertal period.
Our findings also indicate that prepubertal (18-day old) rats were very sensitive to the effects of haloperidol on striatal DA turnover, and Campbell and Baldessar ini (1981) have shown that animals at this age are ex quisitely sensitive to cataleptic effects of neuroleptics. These observations may have some relationship to clin ical observations that indicate that children may be at relatively high risk for developing neuroleptic malig nant syndrome (NMS) during neuroleptic treatment. In children less than 6 years of age, almost all reported cases of NMS occurred after ingestion of only a single dose of neuroleptic (Latz and McCracken 1992) . The fa tality rate from NMS was 13% among adolescent pa tients with NMS (n = 38), and 33% in patients 12 years or younger (n = 11) (Latz and McCracken 1992) .
Our findings also indicate that younger rats have substantially steeper dose-response curves than adults. Evidently, at younger ages, slight diff erences in dose around the EDso can have substantial effects on turn over or metabolite accumulation. This was most clearly seen in the accumbens of 30-day-old rats. Accumulation of HV A and DOPAC were not affected by doses of haloperidol less than or equal to 60 J.. lg/kg (160 nmol/kg), but were increased maximally by doses of only 100 J.. lg/kg (266 nmol/kg). Steep dose-response functions may make it difficult to adjust dose, and they indicate that it may be necessary to switch to a different drug to obtain a more favorable response profIle. This phe nomenon may have relevance to the thorny problem of effectively treating children with Tourette's disorder, without producing undue sedation. Both the high sen sitivity of the accumbens in younger animals and its steep dose-response functions at that age may make it difficult to find a dose of haloperidol that inhibits mo tor tics without interfering excessively with arousal. In some cases, switching to a different agent may be more successful than attempting to titrate dose (Teicher and Glod 1990) .
Overall, the present study adds to our knowledge about important developmental differences in neu rochemical response to antipsychotic drugs. Further re search is in progress to evaluate dose-dependent effects on transmitter release and postsynaptic receptor re sponse to classic antipsychotic drugs and to more selec tive DA receptor antagonists.
